Rituximab for the first-line treatment of chronic lymphocytic leukaemia

NICE technology appraisal guidance [TA174] Published date:

Rituximab is recommended as a possible first treatment for people with chronic lymphocytic leukaemia who are able to take fludarabine in combination with cyclophosphamide.

Rituximab should only be used in combination with fludarabine and cyclophosphamide.

Rituximab is not recommended in combination with any other chemotherapy agents as a first treatment for chronic lymphocytic leukaemia.

Get involved